Ian Shakil - 28 Mar 2024 Form 4/A Insider Report for Augmedix, Inc.

Signature
/s/ Todd Holvick, Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
28 Mar 2024
Net transactions value
-$150,327
Form type
4/A
Filing time
09 Apr 2024, 20:47:13 UTC
Date Of Original Report
01 Apr 2024
Previous filing
27 Feb 2024
Next filing
03 Apr 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AUGX Common Stock Options Exercise $20,476 -31,994 -11% $0.6400 251,654 28 Mar 2024 Direct F1
transaction AUGX Common Stock Sale $129,851 -31,994 -13% $4.06 219,660 28 Mar 2024 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AUGX Stock Option (Right to Buy) Options Exercise $0 -31,994 -25% $0.000000 94,265 28 Mar 2024 Common Stock 31,994 $0.6400 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 This transaction was executed pursuant to a Rule 10b5-1 trading plan.
F2 This transaction was executed in multiple trades ranging from $3.9400 to $4.1600. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
F3 Fully vested.